M&A / Deals Obesity biotech Kailera’s record-breaking IPO PharmaphorumWhen Kailera revealed its plans for an IPO last month, there was a feeling that it could be huge - and that expectation has now been fulfilled.M&A / DealsRead full story pharminent April 17, 2026 (Last updated: April 17, 2026) Pharmaphorum When Kailera revealed its plans for an IPO last month, there was a feeling that it could be huge – and that expectation has now been fulfilled. M&A / DealsRead full story Post navigation Previous: S16 Ep53: Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck – Post-CRT Decisions in the Locally Advanced SettingNext: Lilly’s Foundayo reaches 1,390 patients in first week, trailing Novo’s oral Wegovy launch Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026